Table 1.
Patient Summary (N = 22, except as otherwise indicated)
| Age | |
| Median (range) | 6 y 11 m (11 m-19 y 8 m) |
| Sex | |
| Female | 13 (59%) |
| Male | 9 (41%) |
| Race | |
| White | 18 (82%) |
| Non-White | 4 (18%) |
| Black | 1 |
| Asian | 1 |
| Multiple | 2 |
| Ethnicity | |
| Hispanic | 1 (5%) |
| Non-Hispanic | 21 (95%) |
| Disease | |
| ALL | 8 (36%) |
| B cell | 7 |
| T cell (early T-cell precursor) | 1 |
| AML | 13 (59%) |
| JMML | 1 (5%) |
| Disease status | |
| Refractory/induction failure | 1 (5%) |
| CR1 | 1 (5%) |
| Detectable disease | 1 |
| Subsequent CR | 9 (41%) |
| Detectable disease | 1 |
| Active relapse | 11 (50%) |
| HLA match status | |
| 4 of 8 | 15 (68%) |
| 5 of 8 | 5 (23%) |
| 6 of 8 | 1 (5%) |
| 7 of 8 | 1 (5%) |
| Donor | |
| Mother | 13 (59%) |
| Father | 9 (41%) |
| CMV status (donor/patient) | |
| Negative/negative | 6 (27%) |
| Positive/positive | 11 (50%) |
| Positive/negative | 1 (5%) |
| Negative/positive | 4 (18%) |
| KIR receptor—ligand mismatch (N = 18) | |
| Yes | 10 (56%) |
| No | 8 (44%) |
| HPC product (106/kg) | |
| CD34+ median (range) | 24.65 (4.37−115.56) |
| CD3+ median (range) | 1,239.32 (186.37−3,893.45) |
| NK cell-enriched product (106/kg) (N = 17) | |
| CD56+ median (range) | 14.9 (2.69−70.73) |
| CD3+ CD56− median (range) | 0 (0−0.002) |
ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; JMML = juvenile myelomonocytic leukemia; CR = complete remission; KIR = killer cell immunoglobulin-like receptor; HPC = hematopoietic progenitor cell